| |
Wednesday, November 30, 2022 | 11am ET / 8am PT In this webinar, we will show how data centricity, digitalization and automation streamlines CMC content authoring and why it is the most viable solution to tackle the associated challenges. Register now. 
|
|
Today's Big NewsNov 21, 2022 |
| By Nick Paul Taylor Merck has opened its wallet wide to buy a midphase treatment for life-threatening diseases of the bone marrow, paying $1.35 billion to snap up Imago BioSciences for its oral LSD1 inhibitor bomedemstat. |
|
|
|
By Max Bayer Merck KGaA is turning to business development to bolster its pipeline amid a company-wide effort to massively expedite clinical development. But efforts to become a "leaner" organization may mean layoffs are on the horizon. |
By Max Bayer Amid a tumultuous biotech market, clinical dead ends can be even more financially perilous. This year's Biotech Graveyard takes a look back at some of the companies that were forced to close up shop. |
By Nick Paul Taylor AbbVie and Genmab have glided into Roche’s slipstream in the race to bring a CD3xCD20 bispecific to market, securing FDA priority review and a May decision date—and triggering an $80 million milestone payment in the process. |
|
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now. 
|
|
By James Waldron The Bristol Myers Squibb chief took to the pages of the U.K.’s Financial Times over the weekend to warn that the company expects to halt funding to certain drugs as a result of the government’s drug pricing legislation. |
By Gabrielle Masson Less than a month after unveiling its first gene therapy company, Replay is back again with rare skin disease-focused Telaria. |
By Fraiser Kansteiner On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Teva CEO Kåre Schultz, who is hanging up his CEO hat to retire on Dec. 31. The news comes a little more than two weeks after Teva said it was looking for Schultz’s replacement. |
By Robert King Sens. Bernie Sanders, I-Vermont, and Bill Cassidy, R-Louisiana, are expected to lead the Senate HELP Committee, which has sway over key health policy areas. |
By Nick Paul Taylor The International Space Station National Laboratory is sponsoring another study of drug delivery in the thermosphere, partnering with Houston Methodist Research Institute and SpaceX to test a system in a model orbiting Earth. |
By Heather Landi HC9 Ventures closed its first fund with $83 million to invest in healthcare software and services startups at seed and series A stages. HC9's general partners say the VC firm is unique in its approach to leveraging a deeply engaged investor community and industry expertise to help guide emerging companies. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we share this week's headlines and discuss the 2022 honorees in our annual Fiercest Women in Life Sciences report. |
|
|---|
|
|
|
Tuesday, November 29, 2022 | 2pm ET / 11am PT Process development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise in a field that is very dynamic and accelerating fast. Outsourcing gives you direct access to infrastructure, experience, and a team who has done this before and can quickly generate meaningful data taking the guesswork out of process development. Register now. 
|
|
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
